Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

ConclusionThe occurrence of a flare/IRAE is frequent but mostly manageable without ICI discontinuation in patients with PAD. Immunosuppressive therapy at baseline was associated with poorer outcomes.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - August 4, 2019 Category: Rheumatology Authors: Alice Tison, Gilles Qu éré, Laurent Misery, Elisa Funck‐Brentano, François‐Xavier Danlos, Emilie Routier, Caroline Robert, Yohann Loriot, Olivier Lambotte, Bertille Bonniaud, Camille Scalbert, Sarah Maanaoui, Thierry Lesimple, Stéphan Tags: Full Length Source Type: research